{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,7,30]],"date-time":"2025-07-30T15:55:57Z","timestamp":1753890957323,"version":"3.41.2"},"reference-count":45,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2023,6,20]],"date-time":"2023-06-20T00:00:00Z","timestamp":1687219200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Genet."],"abstract":"<jats:p><jats:bold>Objective:<\/jats:bold> Interferon-\u03b3 (IFN-\u03b3) encoded by IFNG gene is a pleiotropic molecule linked with inflammatory cell death mechanisms. This work aimed to determine and characterize IFNG and co-expressed genes, and to define their implications in breast carcinoma (BRCA).<\/jats:p><jats:p><jats:bold>Methods:<\/jats:bold> Transcriptome profiles of BRCA were retrospectively acquired from public datasets. Combination of differential expression analysis with WGCNA was conducted for selecting IFNG-co-expressed genes. A prognostic signature was generated through Cox regression approaches. The tumor microenvironment populations were inferred utilizing CIBERSORT. Epigenetic and epitranscriptomic mechanisms were also probed.<\/jats:p><jats:p><jats:bold>Results:<\/jats:bold> IFNG was overexpressed in BRCA, and connected with prolonged overall survival and recurrence-free survival. Two IFNG-co-expressed RNAs (AC006369.1, and CCR7) constituted a prognostic model that acted as an independent risk factor. The nomogram composed of the model, TNM, stage, and new event owned the satisfying efficacy in BRCA prognostication. IFNG, AC006369.1, and CCR7 were closely linked with the tumor microenvironment components (e.g., macrophages, CD4\/CD8 T cells, NK cells), and immune checkpoints (notably PD1\/PD-L1). Somatic mutation frequencies were 6%, and 3% for CCR7, and IFNG, and high amplification potentially resulted in their overexpression in BRCA. Hypomethylated cg05224770 and cg07388018 were connected with IFNG and CCR7 upregulation, respectively. Additionally, transcription factors, RNA-binding proteins, and non-coding RNAs possibly regulated IFNG and co-expressed genes at the transcriptional and post-transcriptional levels.<\/jats:p><jats:p><jats:bold>Conclusion:<\/jats:bold> Collectively, our work identifies IFNG and co-expressed genes as prognostic markers for BRCA, and as possible therapeutic targets for improving the efficacy of immunotherapy.<\/jats:p>","DOI":"10.3389\/fgene.2023.1112251","type":"journal-article","created":{"date-parts":[[2023,6,20]],"date-time":"2023-06-20T10:08:08Z","timestamp":1687255688000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":3,"title":["Implications of inflammatory cell death-related IFNG and co-expressed RNAs (AC006369.1 and CCR7) in breast carcinoma prognosis, and anti-tumor immunity"],"prefix":"10.3389","volume":"14","author":[{"given":"Yongran","family":"Deng","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhenlong","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mingmei","family":"Pan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Huayun","family":"Wu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bingqiang","family":"Ni","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xueqiong","family":"Han","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2023,6,20]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"1029","DOI":"10.1080\/15384047.2015.1046646","article-title":"IRF-1 inhibits NF-\u03baB activity, suppresses TRAF2 and cIAP1 and induces breast cancer cell specific growth inhibition","volume":"16","author":"Armstrong","year":"2015","journal-title":"Cancer Biol. Ther."},{"key":"B2","doi-asserted-by":"publisher","first-page":"2930","DOI":"10.1172\/jci91190","article-title":"IFN-\u03b3-related mRNA profile predicts clinical response to PD-1 blockade","volume":"127","author":"Ayers","year":"2017","journal-title":"J. Clin. Invest."},{"key":"B3","doi-asserted-by":"publisher","first-page":"3246","DOI":"10.1200\/jco.22.00338","article-title":"Elacestrant (oral selective estrogen receptor degrader) versus standard endocrine therapy for estrogen receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer: Results from the randomized phase III EMERALD trial","volume":"40","author":"Bidard","year":"2022","journal-title":"J. Clin. Oncol."},{"key":"B4","doi-asserted-by":"publisher","first-page":"108482","DOI":"10.1016\/j.celrep.2020.108482","article-title":"Regulatory T cells support breast cancer progression by opposing IFN-\u03b3-Dependent functional reprogramming of myeloid cells","volume":"33","author":"Clark","year":"2020","journal-title":"Cell Rep."},{"key":"B5","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1016\/j.ejca.2021.10.027","article-title":"Therapeutic vaccines for breast cancer: Has the time finally come?","volume":"160","author":"Corti","year":"2022","journal-title":"Eur. J. Cancer"},{"key":"B6","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1016\/j.immuni.2022.03.007","article-title":"The interferon-stimulated gene RIPK1 regulates cancer cell intrinsic and extrinsic resistance to immune checkpoint blockade","volume":"55","author":"Cucolo","year":"2022","journal-title":"Immunity"},{"key":"B7","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1016\/j.annonc.2021.12.005","article-title":"Tucatinib versus placebo added to trastuzumab and capecitabine for patients with pretreated HER2+ metastatic breast cancer with and without brain metastases (HER2CLIMB): Final overall survival analysis","volume":"33","author":"Curigliano","year":"2022","journal-title":"Ann. Oncol."},{"key":"B8","doi-asserted-by":"publisher","first-page":"e2201166","DOI":"10.1002\/adhm.202201166","article-title":"Site-specific polyplex on CCR7 down-regulation and T cell elevation for lymphatic metastasis blocking on breast cancer","volume":"11","author":"Deng","year":"2022","journal-title":"Adv. Healthc. Mater"},{"key":"B9","doi-asserted-by":"publisher","first-page":"1539","DOI":"10.1038\/sj.leu.2401479","article-title":"Regulation of CD95 expression and CD95-mediated cell death by interferon-gamma in acute lymphoblastic leukemia with chromosomal translocation t(4;11)","volume":"13","author":"D\u00f6rrie","year":"1999","journal-title":"Leukemia"},{"key":"B10","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1002\/path.5902","article-title":"Field cancerization in breast cancer","volume":"257","author":"Gadaleta","year":"2022","journal-title":"J. Pathol."},{"key":"B11","doi-asserted-by":"publisher","first-page":"955979","DOI":"10.3389\/fonc.2022.955979","article-title":"The IFN-\u03b3-related long non-coding RNA signature predicts prognosis and indicates immune microenvironment infiltration in uterine corpus endometrial carcinoma","volume":"12","author":"Gu","year":"2022","journal-title":"Front. Oncol."},{"key":"B12","doi-asserted-by":"publisher","first-page":"100264","DOI":"10.1016\/j.jbc.2021.100264","article-title":"Dicer represses the interferon response and the double-stranded RNA-activated protein kinase pathway in mouse embryonic stem cells","volume":"296","author":"Gurung","year":"2021","journal-title":"J. Biol. Chem."},{"key":"B13","doi-asserted-by":"publisher","first-page":"1338","DOI":"10.1111\/cas.15293","article-title":"CXCL12 promotes CCR7 ligand-mediated breast cancer cell invasion and migration toward lymphatic vessels","volume":"113","author":"Hayasaka","year":"2022","journal-title":"Cancer Sci."},{"key":"B14","doi-asserted-by":"publisher","first-page":"2946","DOI":"10.1200\/jco.21.02772","article-title":"Atezolizumab with neoadjuvant anti-human epidermal growth factor receptor 2 therapy and chemotherapy in human epidermal growth factor receptor 2-positive early breast cancer: Primary results of the randomized phase III IMpassion050 trial","volume":"40","author":"Huober","year":"2022","journal-title":"J. Clin. Oncol."},{"key":"B15","doi-asserted-by":"publisher","first-page":"6195","DOI":"10.3390\/ijms21176195","article-title":"ADAR1 suppresses interferon signaling in gastric cancer cells by MicroRNA-302a-mediated IRF9\/STAT1 regulation","volume":"21","author":"Jiang","year":"2020","journal-title":"Int. J. Mol. Sci."},{"key":"B16","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1186\/1471-2105-9-559","article-title":"Wgcna: an R package for weighted correlation network analysis","volume":"9","author":"Langfelder","year":"2008","journal-title":"BMC Bioinforma."},{"key":"B17","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1016\/j.ccell.2022.02.003","article-title":"CD8(+) T cells and fatty acids orchestrate tumor ferroptosis and immunity via ACSL4","volume":"40","author":"Liao","year":"2022","journal-title":"Cancer Cell"},{"key":"B18","doi-asserted-by":"publisher","first-page":"600","DOI":"10.1016\/j.immuni.2019.01.021","article-title":"CCR7 chemokine receptor-inducible lnc-dpf3 restrains dendritic cell migration by inhibiting HIF-1\u03b1-Mediated glycolysis","volume":"50","author":"Liu","year":"2019","journal-title":"Immunity"},{"key":"B19","doi-asserted-by":"publisher","first-page":"1279","DOI":"10.1093\/annonc\/mdz158","article-title":"A randomised phase II study investigating durvalumab in addition to an anthracycline taxane-based neoadjuvant therapy in early triple-negative breast cancer: Clinical results and biomarker analysis of GeparNuevo study","volume":"30","author":"Loibl","year":"2019","journal-title":"Ann. Oncol."},{"key":"B20","doi-asserted-by":"publisher","first-page":"1190","DOI":"10.1001\/jamaoncol.2022.1488","article-title":"Treatment with adjuvant abemaciclib plus endocrine therapy in patients with high-risk early breast cancer who received neoadjuvant chemotherapy: A prespecified analysis of the monarchE randomized clinical trial","volume":"8","author":"Martin","year":"2022","journal-title":"JAMA Oncol."},{"key":"B21","doi-asserted-by":"publisher","first-page":"1747","DOI":"10.1101\/gr.239244.118","article-title":"Maftools: Efficient and comprehensive analysis of somatic variants in cancer","volume":"28","author":"Mayakonda","year":"2018","journal-title":"Genome Res."},{"key":"B22","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1200\/jco.21.01918","article-title":"Treatment exposure and discontinuation in the PALbociclib CoLlaborative adjuvant study of palbociclib with adjuvant endocrine therapy for hormone receptor-positive\/human epidermal growth factor receptor 2-negative early breast cancer (PALLAS\/AFT-05\/ABCSG-42\/BIG-14-03)","volume":"40","author":"Mayer","year":"2022","journal-title":"J. Clin. Oncol."},{"key":"B23","doi-asserted-by":"publisher","first-page":"R41","DOI":"10.1186\/gb-2011-12-4-r41","article-title":"GISTIC2.0 facilitates sensitive and confident localization of the targets of focal somatic copy-number alteration in human cancers","volume":"12","author":"Mermel","year":"2011","journal-title":"Genome Biol."},{"key":"B24","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1038\/nmeth.3337","article-title":"Robust enumeration of cell subsets from tissue expression profiles","volume":"12","author":"Newman","year":"2015","journal-title":"Nat. Methods"},{"key":"B25","doi-asserted-by":"publisher","first-page":"670188","DOI":"10.3389\/fmed.2021.670188","article-title":"MicroRNA-1-3p suppresses malignant phenotypes of ameloblastoma through down-regulating lysosomal associated membrane protein 2-mediated autophagy","volume":"8","author":"Niu","year":"2021","journal-title":"Front. Med. (Lausanne)"},{"key":"B26","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1186\/s12974-018-1330-2","article-title":"The IFN-\u03b3\/PD-L1 axis between T cells and tumor microenvironment: Hints for glioma anti-PD-1\/PD-L1 therapy","volume":"15","author":"Qian","year":"2018","journal-title":"J. Neuroinflammation"},{"key":"B27","doi-asserted-by":"publisher","first-page":"e47","DOI":"10.1093\/nar\/gkv007","article-title":"Limma powers differential expression analyses for RNA-sequencing and microarray studies","volume":"43","author":"Ritchie","year":"2015","journal-title":"Nucleic Acids Res."},{"key":"B28","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1016\/s1470-2045(19)30689-8","article-title":"Atezolizumab plus nab-paclitaxel as first-line treatment for unresectable, locally advanced or metastatic triple-negative breast cancer (IMpassion130): Updated efficacy results from a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"21","author":"Schmid","year":"2020","journal-title":"Lancet Oncol."},{"key":"B29","doi-asserted-by":"publisher","first-page":"1323","DOI":"10.1200\/jco.21.01506","article-title":"CALGB 40603 (alliance): Long-term outcomes and genomic correlates of response and survival after neoadjuvant chemotherapy with or without carboplatin and bevacizumab in triple-negative breast cancer","volume":"40","author":"Shepherd","year":"2022","journal-title":"J. Clin. Oncol."},{"key":"B30","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1038\/s41467-021-27794-4","article-title":"Genomic alterations and evolution of cell clusters in metastatic invasive micropapillary carcinoma of the breast","volume":"13","author":"Shi","year":"2022","journal-title":"Nat. Commun."},{"key":"B31","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1016\/j.immuni.2022.01.003","article-title":"Interferon-\u03b3 primes macrophages for pathogen ligand-induced killing via a caspase-8 and mitochondrial cell death pathway","volume":"55","author":"Simpson","year":"2022","journal-title":"Immunity"},{"key":"B32","doi-asserted-by":"publisher","first-page":"1361","DOI":"10.1016\/j.ccell.2021.08.005","article-title":"Activating a collaborative innate-adaptive immune response to control metastasis","volume":"39","author":"Sun","year":"2021","journal-title":"Cancer Cell"},{"key":"B33","doi-asserted-by":"publisher","first-page":"209","DOI":"10.3322\/caac.21660","article-title":"Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J. Clin."},{"key":"B34","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1186\/s12943-022-01706-6","article-title":"Crosstalk between 5-methylcytosine and N(6)-methyladenosine machinery defines disease progression, therapeutic response and pharmacogenomic landscape in hepatocellular carcinoma","volume":"22","author":"Tian","year":"2023","journal-title":"Mol. Cancer"},{"key":"B35","doi-asserted-by":"publisher","first-page":"73","DOI":"10.5114\/pm.2022.113834","article-title":"A rare case of invasive micropapillary carcinoma of the breast","volume":"21","author":"Verras","year":"","journal-title":"Prz. Menopauzalny"},{"key":"B36","doi-asserted-by":"publisher","first-page":"41","DOI":"10.2147\/bctt.S346301","article-title":"Micropapillary breast carcinoma: From molecular pathogenesis to prognosis","volume":"14","author":"Verras","year":"","journal-title":"Breast Cancer"},{"key":"B37","doi-asserted-by":"publisher","first-page":"e003539","DOI":"10.1136\/jitc-2021-003539","article-title":"Intermediate monocytes induced by IFN-\u03b3 inhibit cancer metastasis by promoting NK cell activation through FOXO1 and interleukin-27","volume":"10","author":"Wang","year":"","journal-title":"J. Immunother. Cancer"},{"key":"B38","doi-asserted-by":"publisher","first-page":"2756611","DOI":"10.1155\/2022\/2756611","article-title":"Definition of a novel cuproptosis-relevant lncRNA signature for uncovering distinct survival, genomic alterations, and treatment implications in lung adenocarcinoma","volume":"2022","author":"Wang","year":"","journal-title":"J. Immunol. Res."},{"key":"B39","doi-asserted-by":"publisher","first-page":"1968","DOI":"10.1111\/febs.16272","article-title":"Interferon-\u03b3 induces retinal pigment epithelial cell Ferroptosis by a JAK1-2\/STAT1\/SLC7A11 signaling pathway in Age-related Macular Degeneration","volume":"289","author":"Wei","year":"2022","journal-title":"Febs J."},{"key":"B40","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1016\/j.bbi.2019.04.012","article-title":"Mindfulness based stress reduction provides psychological benefit and restores immune function of women newly diagnosed with breast cancer: A randomized trial with active control","volume":"80","author":"Witek Janusek","year":"2019","journal-title":"Brain Behav. Immun."},{"key":"B41","doi-asserted-by":"publisher","first-page":"5086","DOI":"10.7150\/thno.74989","article-title":"UBR5 promotes tumor immune evasion through enhancing IFN-\u03b3-induced PDL1 transcription in triple negative breast cancer","volume":"12","author":"Wu","year":"","journal-title":"Theranostics"},{"key":"B42","doi-asserted-by":"publisher","first-page":"1602","DOI":"10.1002\/hep.32316","article-title":"Hepatic interferon regulatory factor 8 expression suppresses hepatocellular carcinoma progression and enhances the response to anti-programmed cell death protein-1 therapy","volume":"76","author":"Wu","year":"","journal-title":"Hepatology"},{"key":"B43","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1186\/s12957-018-1508-1","article-title":"Assessment of expression of interferon \u03b3 (IFN-G) gene and its antisense (IFNG-AS1) in breast cancer","volume":"16","author":"Yaghoobi","year":"2018","journal-title":"World J. Surg. Oncol."},{"key":"B44","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1089\/omi.2011.0118","article-title":"clusterProfiler: an R package for comparing biological themes among gene clusters","volume":"16","author":"Yu","year":"2012","journal-title":"Omics"},{"key":"B45","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1038\/s41392-021-00629-w","article-title":"Interaction between HLA-G and NK cell receptor KIR2DL4 orchestrates HER2-positive breast cancer resistance to trastuzumab","volume":"6","author":"Zheng","year":"2021","journal-title":"Signal Transduct. Target Ther."}],"container-title":["Frontiers in Genetics"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fgene.2023.1112251\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,6,20]],"date-time":"2023-06-20T10:08:12Z","timestamp":1687255692000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fgene.2023.1112251\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6,20]]},"references-count":45,"alternative-id":["10.3389\/fgene.2023.1112251"],"URL":"https:\/\/doi.org\/10.3389\/fgene.2023.1112251","relation":{},"ISSN":["1664-8021"],"issn-type":[{"type":"electronic","value":"1664-8021"}],"subject":[],"published":{"date-parts":[[2023,6,20]]},"article-number":"1112251"}}